GO
Loading...

Sanofi SA

More

  • Sanofi, Lilly pursue Cialis over-the-counter approval Wednesday, 28 May 2014 | 2:10 AM ET

    PARIS, May 28- Sanofi and Eli Lilly and Co have agreed to pursue regulatory approval for over-the-counter sales of erectile dysfunction treatment Cialis, the French and U.S. drugmakers said in a statement on Wednesday.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • British cost body recommends Sanofi MS drug Lemtrada Tuesday, 27 May 2014 | 7:01 PM ET

    LONDON, May 28- Britain's healthcare cost-effectiveness watchdog is recommending Sanofi's new multiple sclerosis drug Lemtrada as a treatment option on the state health service, it said on Wednesday.

  • Chinese city targets pharma firms in graft crackdown Tuesday, 27 May 2014 | 9:08 AM ET

    SHANGHAI, May 27- China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

  • A bitter pill as China crackdowns squeeze pharma margins Saturday, 24 May 2014 | 10:00 PM ET

    China has been a magnet for the big global pharmaceutical companies and other healthcare firms as growth slows in Europe and the United States. While global drugmakers withhold their China profit figures, the analysis suggests profit growth is harder to come by- a concern as many global firms look to China as a future growth driver.

  • Why there's no end in sight for higher drug costs Thursday, 22 May 2014 | 7:06 AM ET
    About 40 protesters from across the country converged on Gilead Sciences headquarters in Foster City, Calif., Nov. 14, 2012, calling on the drug maker to lower prices for its Stribild AIDS medication.

    The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.

  • *China anti-trust watchdog visits Roche office. *China cracking down on wider pharma sector. SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said it had been visited by a unit of China's anti-trust regulator- a move that comes amid a widening crackdown on corruption and high prices in the country's pharmaceutical sector.

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • PARIS, May 15- France's decision to expand its veto powers over strategic sectors to give it some leverage on the future of engineering group Alstom reflects a rare area of policy consensus that resonates across the political spectrum.

  • *Sanofi has restructured R&D, has strong pipeline-Zerhouni. PARIS, May 15- France's Sanofi has strengthened its drug pipeline and has enough future blockbusters lined up for it to steer clear of the M&A frenzy "overheating" the industry, the drugmaker's R&D chief told Reuters.

  • SHANGHAI, May 15- GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investigation said.

  • SHANGHAI, May 15- GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investigation said.

  • Midday movers: Aaron's, Eli Lilly, Gogo & More Monday, 12 May 2014 | 12:30 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • May 12- Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials. Sanofi's Lantus is the world's most prescribed insulin product with quarterly worldwide sales of about $2 billion. The drug will lose U.S. patent protection in February 2015.

  • May 12- Eli Lilly and Co said its type 2 diabetes treatment was as effective as Sanofi SA's approved drug Lantus in reducing patients' blood sugar levels in three late-stage trials.

  • Early movers: PF, AZN, PFE, CS, P & more Monday, 12 May 2014 | 7:46 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • May 11- U.S. medical firm Allergan Inc declined to comment on Sunday on a report that it has been seeking offers from rival companies to combat Valeant Pharmaceuticals International's $47 billion cash and share offer.

  • PARIS, May 7- Economy Minister Arnaud Montebourg stepped up France's push for a weaker euro on Wednesday, saying political leaders had the right to assess the right level for the currency in a position completely at odds with Germany's.

  • FACTBOX-M&A frenzy transforming global pharma Tuesday, 6 May 2014 | 2:00 PM ET

    MAY May 6- Merck& Co Inc agrees to sell its consumer care business to Germany's Bayer AG for $14.2 billion. May 2- Pfizer Inc raises its offer for AstraZeneca Plc to 63 billion pounds, but the British company promptly rejects the proposal, which would create the world's biggest pharmaceuticals company.

  • Aspirin and suntan lotion? Bayer, Merck do deal Tuesday, 6 May 2014 | 7:13 AM ET
    Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Bayer will acquire the consumer care business of U.S.-based Merck & Co for $14.2 billion in cash, the company said in a statement Tuesday.